SOAT1 and diabetic kidney disease: Although direct experimental IgAN models demonstrating JAK/STAT inhibition efficacy are pending, extensive evidence from diabetic nephropathy models, in which STAT3 pathway blockade reduced proteinuria and histological injury, supports the potential of JAK/STAT targeting.